PruGen Pharmaceuticals Selects IQVIA’s OCE Technology Platform to Advance Field Sales and Home Office Effectiveness

Breakthrough Technology for Better Decision Making and Customer

(NYSE:IQV), a company dedicated to applying advanced analytics and
technology to help healthcare clients find better solutions for
patients, today announced that PruGen
has selected Orchestrated
Customer Engagement (OCE)
, IQVIA’s next-generation commercial
technology platform to help increase the efficiency and effectiveness of
the company’s commercial teams.

The innovative technology and superior usability built into the OCE
platform, in addition to a high level of satisfaction with IQVIA as a
long-standing collaborator, were primary decision-making factors for
PruGen. According to the agreement, PruGen’s dermatology specialty sales
force and home office operations team will use OCE.

“OCE received overwhelming support from the sales staff who saw the
solution,” said Matt Raiff, chief operating officer of PruGen. “The
usability will increase adoption, so reports and analytics will be more
accurate and valuable. The data shared between marketing, sales, home
office and other departments will help us drive collaboration and,
therefore, more productive customer interactions.”

OCE is built on best-in-class technologies, including,
MuleSoft and Amazon Web Services and others to provide seamless
integration. The solution features Ada™, artificial intelligence that
gives recommendations for next-best actions; Apollo™, an intuitive user
interface; and Lexi™, an integration platform as a service (iPaaS) to
connect all applications and data using common language.

“PruGen wanted to take advantage of the latest technology that can
transform their business, and IQVIA is able to deliver that with OCE,”
said Mark Karch, vice president of sales, Technology Solutions US,
IQVIA. “They have grown dramatically in the past few years, and that
momentum is continuing. OCE is a solution that can grow and scale with
them, and fit well in their expanding IT ecosystem with the integration
capability of Lexi and other key benefits.”

About PruGen Pharmaceuticals

PruGen Pharmaceuticals provides high quality products, exclusively to
specialists that meet the real needs of patients while offering easy
access and great value in treating skin care conditions. Our commitment
is not only to provide the highest quality products, but also to make
sure patients have convenient access and affordable pricing for the
treatment of their condition.

Our heritage and our values are at the foundation of our company and
while we offer innovative and cost-effective products we also focus on
our delivery of excellent customer service to the patients and providers
that utilize our products. Our commitment to patient access is at the
heart of our business and in the hearts and minds of our employees as we
continue to grow our product portfolio. To learn more, visit


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions, and contract research services to the life
sciences industry. Formed through the merger of IMS Health and
Quintiles, IQVIA applies human data science — leveraging the analytic
rigor and clarity of data science to the ever-expanding scope of human
science — to enable companies to reimagine and develop new approaches to
clinical development and commercialization, speed innovation, and
accelerate improvements in healthcare outcomes. Powered by the IQVIA
CORE™, IQVIA delivers unique and actionable insights at the intersection
of large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps customers drive human health outcomes
forward. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap into a
deeper understanding of diseases, human behaviors and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit

here to subscribe to Mobile Alerts for IQVIA


IQVIA Media Relations
Tor Constantino, +1-484-567-6732
Investor Relations
Andrew Markwick, +1-973-257-7144